BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 33844952)

  • 1. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelofibrosis: an update on current pharmacotherapy and future directions.
    Cervantes F; Martinez-Trillos A
    Expert Opin Pharmacother; 2013 May; 14(7):873-84. PubMed ID: 23514013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacotherapeutic management of patients with myelofibrosis: looking beyond JAK inhibitors.
    Duminuco A; Vetro C; Giallongo C; Palumbo GA
    Expert Opin Pharmacother; 2023; 24(13):1449-1461. PubMed ID: 37341682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors.
    Waksal JA; Mascarenhas J
    Curr Hematol Malig Rep; 2022 Oct; 17(5):140-154. PubMed ID: 35984598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I treat myelofibrosis.
    Cervantes F
    Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational non-JAK inhibitors for chronic phase myelofibrosis.
    Bankar A; Gupta V
    Expert Opin Investig Drugs; 2020 May; 29(5):461-474. PubMed ID: 32245330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clarifying the use of ruxolitinib in patients with myelofibrosis.
    Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
    Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel treatments to tackle myelofibrosis.
    Zimran E; Keyzner A; Iancu-Rubin C; Hoffman R; Kremyanskaya M
    Expert Rev Hematol; 2018 Nov; 11(11):889-902. PubMed ID: 30324817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the treatment of Myelofibrosis.
    Shreenivas A; Mascarenhas J
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):37-49. PubMed ID: 29480036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing patients with myelofibrosis and low platelet counts.
    Al-Ali HK; Vannucchi AM
    Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel treatments for myelofibrosis: beyond JAK inhibitors.
    Tremblay D; Mesa R
    Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
    Tibes R; Mesa RA
    J Hematol Oncol; 2014 Mar; 7():18. PubMed ID: 24598114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelofibrosis in 2019: moving beyond JAK2 inhibition.
    Schieber M; Crispino JD; Stein B
    Blood Cancer J; 2019 Sep; 9(9):74. PubMed ID: 31511492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations.
    Gill H; Leung GMK; Kwong YL
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):667-675. PubMed ID: 38066870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Stem Cell Transplantation in Myelofibrosis.
    Jain T; Mesa RA; Palmer JM
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1429-1436. PubMed ID: 28499938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.